Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05271084
Other study ID # HMU PE-EC 16112021/382
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date November 10, 2021
Est. completion date June 8, 2022

Study information

Verified date September 2022
Source Hawler Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to test if combining the antidepressant Citalopram with Pentoxifylline (PTX), a medicine with anti-inflammatory and phosphodiesterase inhibitory properties, enhanced antidepressant efficacy in adult patients with major depressive disorder (MDD) when compared to Citalopram alone.


Description:

According to mounting evidence, inflammation and phosphodiesterase (PDE) pathways may play a role in the pathogenesis of psychiatric diseases such as MDD. PTX is a phosphodiesterase inhibitor and has anti-inflammatory and antioxidant effects. Therefore, it has been hypothesized that MDD patients taking combined administration of the Citalopram, a Selective Serotonin Reuptake Inhibitor (SSRI), and PTX would show a higher improvement in depression symptoms. The relationship between the Hamilton Depression Rating Scale-17 items (Ham-D-17) score and various biological markers and their potential role in the therapeutic outcome of MDD will be assessed.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date June 8, 2022
Est. primary completion date February 25, 2022
Accepts healthy volunteers No
Gender All
Age group 21 Years to 65 Years
Eligibility Inclusion Criteria: - Provide written, voluntary informed consent prior to study enrollment. - Male or female between the ages of 21 to 65. - Patient must be diagnosed with a moderate to a severe depressive episode, as determined by the MADRS score >21. - Prior to taking part in the trial, all patients were requested to abstain from all psychotropic and anti-inflammatory medications for at least four weeks. Exclusion Criteria: - Current psychotic symptoms or perceptual problems of any kind, at the discretion of the investigator - The presence of a contraindication to PTX, such as a drug allergy or xanthine derivative allergy - The presence of cardiovascular diseases, including high blood pressure, a recent myocardial infarction, cardiac arrhythmia, coronary artery disease, or a coagulation disorder - Renal impairment, defined as creatinine clearance less than 80ml/min - Patients who have previously received electroconvulsive therapy (ECT) - Patients who have inflammatory disorders - Patients with a concurrent active medical condition - Patients with a history of seizures - Patients who are pregnant or nursing females. - Patients with bipolar I or bipolar II disorder - Patients with personality disorders - Patients with eating disorders - Patients with substance dependence or abuse

Study Design


Intervention

Drug:
Citalopram (tablet) 20 mg + Pentoxifylline (tablet) 400Mg
Selective serotonin reuptake inhibitor (SSRI) + phosphodiesterase inhibitor with anti-inflammatory properties
Citalopram (tablet) 20 mg + Placebo (tablet)
Selective serotonin reuptake inhibitor (SSRI) + placebo

Locations

Country Name City State
Iraq Hawler Psychiatric Hospital and Private Clinic Erbil

Sponsors (1)

Lead Sponsor Collaborator
Hawler Medical University

Country where clinical trial is conducted

Iraq, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hamilton Depression Rating Scale 17 (HDRS-17) Scores (Time Frame: Baseline, week 2,4,6,8,10, and12) The HDRS is a 17-item scale that asks participants to rate the severity of their depression symptoms. Scoring is based on the 17-item scale. The total score ranges from 0 to 52, with higher numbers demonstrating more severe symptoms. Normal scores range from 0 to 7, mild depression ranges from 8 to 16, moderate depression ranges from 17 to 23, and scores of 24 and greater indicate severe depression. Remission is defined as HDRS total score = 7 (primary outcome). 12 weeks
Secondary Effect on the serum level of tumor necrosis factor-alpha (TNF-a) Peripheral blood samples will be obtained and serum levels of TNF-a ( pg/mL) will be measured at baseline and after treatment (week 12) 12 weeks
Secondary Effect on the serum level of circulating C-reactive protein (CRP) Peripheral blood samples will be obtained and serum levels of CRP (mg/dL) will be measured at baseline and after treatment (week 12) 12 weeks
Secondary Effect on the serum level of interleukin 6 (IL-6) Peripheral blood samples will be obtained and serum levels of IL-6 (pg/mL) will be measured at baseline and after treatment (week 12) 12 weeks
Secondary Effect on the serum level of interleukin-1-ß (IL-1-ß) Peripheral blood samples will be obtained and serum levels of IL-1-ß (pg/mL) will be measured at baseline and after treatment (week 12) 12 weeks
Secondary Effect on the serum level of interleukin-10 (IL-10) Peripheral blood samples will be obtained and serum levels of IL-10 (pg/mL) will be measured at baseline and after treatment (week 12) 12 weeks
Secondary Effect on the serum level of brain derived neurotrophic factor (BDNF) Peripheral blood samples will be obtained and serum levels of BDNF (ng/mL) will be measured at baseline and after treatment (week 12) 12 weeks
Secondary Effect on the serum level of serotonin Peripheral blood samples will be obtained and serum levels of serotonin (ng/mL) will be measured at baseline and after treatment (week 12) 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4